ENDPOINTS

AbbVie and Sandoz resolve court spat over Rinvoq patents

AbbVie and Sandoz have resolved their patent dispute over AbbVie’s blockbuster i...

CDC vaccine advisors set to meet this week after two-mo...

A panel of experts who decide the national immunization schedule will meet on Tu...

BioNTech-backed ADC maker DualityBio plans Hong Kong IPO

Antibody-drug conjugates startup Duality Biologics will join the public markets ...

AMA asks UnitedHealth to relax cyberattack loan recoupment

The American Medical Association is urging Optum, a unit of UnitedHealth Group, ...

FDA's union readies negotiations with HHS over some fir...

A union that represents more than 11,000 FDA employees nationwide — the National...

Sandoz sues Amgen over nearly decadelong launch delay f...

Amgen has enjoyed a monopoly on its blockbuster inflammatory disease drug Enbrel...

Pfizer's next move after ending work on oral obesity dr...

On Monday, Pfizer announced it had given up on danuglipron, the company's closel...

Primate researchers gird for funding cuts as NIH fights...

The government is fighting in court for a plan to cut spending on overhead resea...

Ironwood to look for alternative paths after FDA asks f...

Ironwood Pharmaceuticals is now working with Goldman Sachs in its hunt for compa...

Pharma tariffs to arrive 'in the next month or two,' co...

Commerce Secretary Howard Lutnick has indicated more specific timelines as to wh...

Verve unveils early data from second attempt at heart d...

Verve Therapeutics is trying to swerve the gene editing industry downturn with n...

Pharma tariffs to arrive 'in the next month or two,' Co...

Commerce Secretary Howard Lutnick has indicated more specific timelines as to wh...

In a blow to its obesity pipeline, Pfizer drops danugli...

Pfizer has discontinued its once-daily obesity pill danuglipron after a patient ...

Biotech’s survival guide; What tariffs could mean for p...

Welcome back to Endpoints Weekly! This week's recap kicks off with Andrew Dunn's...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.